Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Warner Chilcott

Executive Summary

Warner Chilcott: Initial public offering will consist of 3 mil. American Depositary Shares at a price between $16 and $18 per ADS. One ADS represents one ordinary share of the complex generics and specialty branded products company, formerly the generics division of Warner-Lambert; Warner Chilcott was sold to Elan in 1996 and joined with Elan's generics subsidiary Nale. Cowen & Co., Dillon Read and Oppenheimer & Co. will manage the IPO and hold an overallotment option of 450,000 ADS. The IPO is expected to be priced in the first week of August. In conjunction with the IPO, Barr will make an initial equity investment in Warner Chilcott worth $5 mil.; Barr may double the investment within four years. Warner Chilcott will use Barr to manufacture and distribute "certain generic versions of its branded products," Barr says. Barr will "capitalize on Warner Chilcott's trusted medical heritage and brand equity...for certain branded products as well as future NDA products"...

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts